BioCentury
ARTICLE | Clinical News

Merck KGaA reports Phase I response data for M7824 in NSCLC

July 13, 2018 7:16 PM UTC

Merck KGaA (Xetra:MRK) reported response data at the American Society of Clinical Oncology (ASCO) meeting in Chicago from a cohort of patients with advanced non-small cell lung cancer in a Phase I trial of M7824.

In 27 PD-L1-positive patients, the recommended Phase II dose of 1,200 mg IV every two weeks led to an investigator-assessed confirmed overall response rate (ORR) of 40.7% and a median progression-free survival (PFS) of 6.8 months. In seven patients with high PD-L1 expression, that dose led to an ORR of 71.4% and median PFS was not reached...